Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications

2026-02-05 - 13:37

NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source. Unlike ISM8969, Insilico’s brain-penetrant NLRP3 pipeline already with FDA IND clearance, ISM5059 features a completely different chemical core designed for peripheral-restricted potency.